<DOC>
	<DOCNO>NCT02327624</DOCNO>
	<brief_summary>The principal hypothesis study two different maintenance regimen ticagrelor safe , tolerable associate significant inhibition erythrocyte adenosine reuptake compare clopidogrel patient undergo elective Percutaneous Coronary Intervention ( PCI ) stable Coronary artery disease ( CAD ) .</brief_summary>
	<brief_title>STEEL Percutaneous Coronary Intervention</brief_title>
	<detailed_description>Coronary artery disease ( CAD ) cause fatty deposit building time artery supply heart blood , cause artery narrow reduce amount blood get heart . One treatment option CAD percutaneous coronary intervention ( PCI ) balloon insert artery supply heart open artery narrow . A stent leave artery balloon remove hold artery open allow blood flow heart . One risks procedure , CAD , formation blood clot block artery , stop reduce blood flow cause heart attack . Platelets small blood cell involve formation blood clot cause heart attack . Antiplatelet drug ( e.g . aspirin ) give patient CAD reduce risk clot form future cause heart attack . In recent large clinical trial ( PLATO study ) , show heart attack patient treat new antiplatelet medication ( ticagrelor ) few later heart attack compare current standard treatment ( clopidogrel ) . The STEELPCI study compare three different strategy prescribe antiplatelet medication patient stable CAD PCI . Patients wait list PCI meet study inclusion/exclusion criterion invite participate . Patients PCI normal randomise take one three different medication strategy , either clopidogrel one two dos ticagrelor . Patient take medication 30 day blood test meet research team time assess effect medication strategy .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Male female age great 18 year 3 . Previous invasive coronary angiography plan PCI coronary stent implantation stable coronary artery disease 1 . Requirement chronic total occlusion cross order stent implantation proceed 2 . Plan coronary angiography view PCI appropriate ( i.e . current coronary anatomy know ) 3 . Intention use platelet function test genotyping guide antiplatelet therapy 4 . Known allergy intolerance aspirin , clopidogrel ticagrelor 5 . Treatment antiplatelet medication apart aspirin clopidogrel stop 10 day prior PCI ( e.g . ticagrelor , prasugrel , dipyridamole , ticlopidine , abciximab , tirofiban ) , example continue indication 6 . Planned treatment consideration treatment oral antiplatelet medication aspirin clopidogrel follow PCI 7 . Planned use glycoprotein IIb/IIIa antagonist PCI procedure 8 . Myocardial infarction within past 12 month 9 . Current plan use oral anticoagulant ( e.g . warfarin , dabigatran , rivaroxaban , apixaban ) 10 . Previous history intracranial haemorrhage intracranial pathology associate increase bleed risk 11 . Haemoglobin &lt; 100 g/L evidence active bleeding 12 . Peptic ulceration document endoscopy within last 3 month unless heal proven repeat endoscopy 13 . History acute chronic liver disease ( e.g . cirrhosis ) 14 . Treatment last 10 day requirement ongoing treatment strong CYP3A4 inhibitor inducer ( see section 5.6.8 ) 15 . Requirement ongoing treatment simvastatin lovastatin dose great 40 mg per day 16 . Treatment CYP3A4 substrate narrow therapeutic index ( e.g . cyclosporine , quinidine ) 17 . Endstage renal failure require dialysis 18 . History alcohol drug abuse last year 19 . Comorbidity associate life expectancy le 1 year 20 . Females childbearing potential unless negative pregnancy test screen willing use effective contraception ( i.e . establish use oral , injected implant hormonal method contraception placement intrauterine device ( IUD ) intrauterine system ( IUS ) barrier method contraception spermicide sole male partner prior vasectomy confirm absence sperm ejaculate ) duration treatment study medication 21 . Any condition deem investigator place patient excessive risk bleed ticagrelor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>